3,4-Dihydroxybenzylamine hydrobromide

SKU: orb1310059

Description

This small molecule, 3,4-Dihydroxybenzylamine hydrobromide, acts as a DNA polymerase inhibitor, demonstrating anti-proliferative effects across multiple melanoma cell lines irrespective of their tyrosinase activity levels. It is a research tool for investigating melanoma biology and evaluating potential chemotherapeutic mechanisms in vitro.

Research Area

Cell Biology, Molecular Biology

Key Properties

• CAS Number: 16290-26-9
• MW: 220.06
• Purity: 97.28% (May vary between batches)
• Formula: C₇H₁₀BrNO₂
• SMILES: Br.NCc1ccc(O)c(O)c1
• Target: DNA/RNA Synthesis
• Solubility: DMSO:80 mg/mL (363.54 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (15 mM)

Bioactivity

• In Vivo:
  3,4-Dihydroxybenzylamine hydrobromide (200, 400, 600 and 800 mg/kg; i.p.; 21 days) has different effects at different doses, the median life-span are 17, 24.5, 26, 29 and 25 days respectively. 3,4-Dihydroxybenzylamine hydrobromide (1000 mg/kg; i.p.; 7 days) has the least toxic effect in non-tumor-bearing B6D2F1 mice,and mice is tolerated at this dose.
  Read more...
• In Vitro:
  3,4-Dihydroxybenzylamine hydrobromide (1 μM-10 mM; 48 hours) inhibits the growth of melanoma cell lines with IC50 values of 30, 84, 90, and 68 μM for SK-MEL-30, SK-MEL-2, SK-MEL-3, and RPMI-7951 cells, respectively, and exhibits IC50 values of 10, 25, 67, and 184 μM for S91A, S91B, L1210, and SCC-25 cells. Cytotoxicity in SK-MEL-2 and SK-MEL-28 is enhanced by buthionine sulfoximine (BSO), decreasing the IC50 values of 3,4-DHBA by 127% in SK-MEL-28 and by 148% in SK-MEL-2 cells.
  Read more...
• Cell Research:
  Cell Line: Human and Murine Melanoma Cell Lines; Non-Melanoma Cell Lines Concentration: 1 μM-10 mM Incubation Time: 48 hours
• Animal Research:
  Animal Model: C57BL/6 mice with B6D2F1 cells Dosage: 200 mg/kg, 400 mg/kg, 600 mg/kg, and 800 mg/kg Administration: Intraperitoneal injection

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

RNA Synthesis, RNASynthesis, tyrosinase, Tumor, 3,4 Dihydroxybenzylamine hydrobromide, 3,4-Dihydroxybenzylamine, 3,4Dihydroxybenzylamine hydrobromide, 3,4-Dihydroxybenzylamine Hydrobromide, DNA/RNA Synthesis, DNA Synthesis, DNA polymerase, DNASynthesis, NSC263475, NSC-263475, NSC263475 Hydrobromide, NSC-263475 Hydrobromide, NSC 263475 Hydrobromide, NSC 263475, NSC 263475 hydrobromide, inhibit, Inhibitor, melanoma

Compound Identifiers

PubChem CID

13343562